#MyEAS2025 The live discussion of my case on statin intolerance at #EASCongress2025 was truly exciting! The EAS Stage was packed—much more than the photo shows—and the audience was incredibly engaged. Big thanks to everyone who joined for this rewarding discussion! @eassociety.bsky.social

#MyEAS2025 Honored to join as a panelist at #EASCongress2025 in a session on the power of SoMe in science & networking. Sharing how these platforms launched my journey into ath was truly exciting—and I hope it inspires other early-career researchers! @eassociety.bsky.social @katioorni.bsky.social

💡 Key takeaway in one line! #EASCongress2025 #MyEAS2025 @eassociety.bsky.social
Excited to share the latest breakthroughs in lipid research and clinical practice. Here’s a quick snapshot of yesterday's late-breaking findings 👇

The BROADWAY study results are out now in @nejm.org, published simultaneously with their presentation at #EASCongress2025 🙌 So if you missed Prof. Nicholls' talk—you can catch up here www.nejm.org/doi/full/10....
#EASCongress2025 #MyEAS2025 @maciejbanach.bsky.social @eassociety.bsky.social

Obicetrapib was well tolerated in the BROADWAY study. Long-term effects on CV outcomes will be evaluated in the ongoing PREVAIL trial—but current results suggest it holds considerable promise for improving lipid control in high CV risk patients #EASCongress2025 #MyEAS2025 @eassociety.bsky.social

BROADWAY Study: Additionally, obicetrapib led to a placebo-adj 33.5% reduction in Lp(a), independent of its effects on other lipid parameters and HDL-C increase. The broader lipid effects are also very encouraging #EASCongress2025 #MyEAS2025 @eassociety.bsky.social

BROADWAY study: Obicetrapib, added to maximally tolerated LLT in high-risk CV patients, reduced placebo-adjusted LDL-C by 32.6% at day 84 and 24% at day 365, with 51% of patients reaching LDL-C <55 mg/dL #EASCongress2025 #MyEAS2025 @eassociety.bsky.social

The results of the TANDEM trial have been published in @thelancet.bsky.social , simultaneously with their presentation at the #EASCongress2025! Read the full article here: doi.org/10.1016/S014...
@erinmichos.bsky.social @eassociety.bsky.social #MyEAS2025

Beyond LDL-C, the TANDEM trial showed very encouraging results on ApoB and a high proportion of patients reaching lipid targets. The fixed-dose combo was also well tolerated #EASCongress2025 #MyEAS2025 @eassociety.bsky.social

The TANDEM trial: the fixed-dose combo of obicetrapib + ezetimibe cut LDL-C by nearly 50%, with over 70% of participants reaching levels below 1.4 mmol/L. A promising step forward in lipid lowering! #EASCongress2025 #MyEAS2025 @eassociety.bsky.social

What does EAS Young Fellows Programm mean?? It means SCIENCE, PASSION, FRIENDSHIP & a touch of ART — all in one squad! Loving the energy at #EASCongress2025 #EASYoungFellows #MyEAS2025 #AtheroTalk

#EASCongress2025 Late Breakers - Key takeaway in one line! #MyEAS2025
Check out the slide below for a one-line summary of each late-breaking presentation — concise, clear, and all in one place 😎 @eassociety.bsky.social

The posters are up! 🙌 It’s such an exciting moment to see our research shared with the #EASCongress2025 community. Can’t wait for all the inspiring conversations and new ideas that will come from these next few days!
@eassociety.bsky.social @afgciceromd.bsky.social #MyEAS2025